Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Vertex Pharms Inc Drug Patent Portfolio

Vertex Pharms Inc owns 4 orange book drugs protected by 49 US patents Given below is the list of Vertex Pharms Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10793547 Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator 08 Dec, 2037
Active
US11179367 Pharmaceutical compositions for treating cystic fibrosis 08 Dec, 2037
Active
US11453655 Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator 08 Dec, 2037
Active
US11517564 Methods of treatment for cystic fibrosis 08 Dec, 2037
Active
US10758534 NA 06 Oct, 2035
Active
US11426407 Modulators of cystic fibrosis transmembrane conductance regulator 06 Oct, 2035
Active
US10206877 Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases 14 Apr, 2035
Active
US11951212 Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases 14 Apr, 2035
Active
US10058546 Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof 15 Jul, 2033
Active
US9012496 Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof 15 Jul, 2033
Active
US10272046 Pharmaceutical composition and administrations thereof 27 Feb, 2033
Active
US11147770 Pharmaceutical composition and administrations thereof 27 Feb, 2033
Active
US11752106 Pharmaceutical composition and administrations thereof 27 Feb, 2033
Active
US8883206 Pharmaceutical composition and administrations thereof 27 Feb, 2033
Active
US10081621 Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide 25 Mar, 2031
Active
US11578062 Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide 25 Mar, 2031
Active
US8993600 Modulators of ATP-binding cassette transporters 11 Dec, 2030
Active
US8507534 Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid 20 Sep, 2030
Active
US8716338 Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid 20 Sep, 2030
Active
US9192606 Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid 29 Sep, 2029
Active
US10646481 Pharmaceutical composition and administrations thereof 13 Aug, 2029
Active
US11564916 Pharmaceutical composition and administrations thereof 13 Aug, 2029
Active
US8846718 Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid 02 Jul, 2029
Active
US10076513 Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof 04 Dec, 2028
Active
US10597384 Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid 04 Dec, 2028
Active
US11052075 Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof 04 Dec, 2028
Active
US12065432 Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid 04 Dec, 2028
Active
US8653103 Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid 04 Dec, 2028
Active
US9150552 Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid 04 Dec, 2028
Active
US8415387 Modulators of ATP-binding cassette transporters 12 Nov, 2027
Active
US8324242 Modulators of ATP-binding cassette transporters 05 Aug, 2027
Active
US7776905 Modulators of ATP-binding cassette transporters 03 Jun, 2027
Active
US7495103 Modulators of ATP-binding cassette transporters 20 May, 2027
Active
US7645789 Indole derivatives as CFTR modulators 01 May, 2027
Active
US8598181 Modulators of ATP-binding cassette transporters 01 May, 2027
Active
US8623905 Modulators of ATP-binding cassette transporters 01 May, 2027
Active
US10022352 Modulators of ATP-binding cassette transporters 09 Apr, 2027
Active
US10239867 Modulators of ATP-binding cassette transporters 09 Apr, 2027
Active
US11639347 Modulators of ATP-binding cassette transporters 09 Apr, 2027
Active
US9974781 Modulators of ATP-binding cassette transporters 09 Apr, 2027
Active
US8410274 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
Active
US8754224 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
Active
US9670163 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
Active
US9931334 Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
Active
US7973038 Modulators of ATP-binding cassette transporters 08 Nov, 2026
Active
US8741933 Modulators of ATP-binding cassette transporters 08 Nov, 2026
Active
US9216969 Modulators of ATP-binding cassette transporters 08 Nov, 2026
Active
US8354427 Modulators of ATP-binding cassette transporters 06 Jul, 2026
Active
US8629162 Modulators of ATP-binding cassette transporters 24 Jun, 2025
Active


Given below is the list of recent legal activities going on the following drug patents of Vertex Pharms Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 15 Jul, 2024 US8354427
Payment of Maintenance Fee, 12th Year, Large Entity 04 Jun, 2024 US8324242 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 04 Jun, 2024 US8324242 (Litigated)
Email Notification
Critical
09 Apr, 2024 US11951212
Recordation of Patent eGrant 09 Apr, 2024 US11951212
Recordation of Patent Grant Mailed
Critical
09 Apr, 2024 US11951212
Patent Issue Date Used in PTA Calculation
Critical
09 Apr, 2024 US11951212
Patent eGrant Notification 09 Apr, 2024 US11951212
Mail Patent eGrant Notification 09 Apr, 2024 US11951212
Payment of Maintenance Fee, 4th Year, Large Entity 08 Apr, 2024 US10793547
Email Notification
Critical
21 Mar, 2024 US11951212
Issue Notification Mailed
Critical
20 Mar, 2024 US11951212
Application Is Considered Ready for Issue
Critical
05 Mar, 2024 US11951212
Dispatch to FDC 05 Mar, 2024 US11951212
Payment of Maintenance Fee, 4th Year, Large Entity 01 Mar, 2024 US10758534


Vertex Pharms Inc Drug Patents' Oppositions Filed in EPO

Vertex Pharms Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 18, 2017, by Alfred E. Tiefenbacher (Gmbh & Co. Kg). This opposition was filed on patent number EP11715637A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP17204189A Sep, 2021 STADA Arzneimittel AG Granted and Under Opposition
EP17204189A Sep, 2021 Lederer & Keller Patentanwälte Partnerschaft mbB Granted and Under Opposition
EP17204189A Sep, 2021 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP15849396A May, 2021 Generics [UK] Limited Granted and Under Opposition
EP10708442A Oct, 2019 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP15721912A Feb, 2019 Generics (U.K.) Limited Granted and Under Opposition
EP06848237A Nov, 2017 Georg Kalhammer/Stephan Teipel Opposition rejected
EP11715637A May, 2017 Alfred E. Tiefenbacher (GmbH & Co. KG) Patent maintained as amended


Vertex Pharms Inc's Family Patents

Vertex Pharms Inc drugs have patent protection in a total of 45 countries. It's US patent count contributes only to 24.0% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Vertex Pharms Inc Drug List

Given below is the complete list of Vertex Pharms Inc's drugs and the patents protecting them.


1. Kalydeco

Kalydeco is protected by 13 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10272046 Pharmaceutical composition and administrations thereof 27 Feb, 2033
(8 years from now)
Active
US11147770 Pharmaceutical composition and administrations thereof 27 Feb, 2033
(8 years from now)
Active
US11752106 Pharmaceutical composition and administrations thereof 27 Feb, 2033
(8 years from now)
Active
US8883206 Pharmaceutical composition and administrations thereof 27 Feb, 2033
(8 years from now)
Active
US10646481 Pharmaceutical composition and administrations thereof 13 Aug, 2029
(4 years from now)
Active
US11564916 Pharmaceutical composition and administrations thereof 13 Aug, 2029
(4 years from now)
Active
US8324242 Modulators of ATP-binding cassette transporters 05 Aug, 2027
(2 years from now)
Active
US7495103 Modulators of ATP-binding cassette transporters 20 May, 2027
(2 years from now)
Active
US8410274 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
(2 years from now)
Active
US8754224 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
(2 years from now)
Active
US9670163 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
(2 years from now)
Active
US8354427 Modulators of ATP-binding cassette transporters 06 Jul, 2026
(1 year, 8 months from now)
Active
US8629162 Modulators of ATP-binding cassette transporters 24 Jun, 2025
(8 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kalydeco's drug page


2. Orkambi

Orkambi is protected by 22 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8993600 Modulators of ATP-binding cassette transporters 11 Dec, 2030
(6 years from now)
Active
US8507534 Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid 20 Sep, 2030
(5 years from now)
Active
US8716338 Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid 20 Sep, 2030
(5 years from now)
Active
US9192606 Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid 29 Sep, 2029
(4 years from now)
Active
US10646481 Pharmaceutical composition and administrations thereof 13 Aug, 2029
(4 years from now)
Active
US11564916 Pharmaceutical composition and administrations thereof 13 Aug, 2029
(4 years from now)
Active
US8846718 Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid 02 Jul, 2029
(4 years from now)
Active
US10076513 Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof 04 Dec, 2028
(4 years from now)
Active
US10597384 Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid 04 Dec, 2028
(4 years from now)
Active
US11052075 Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof 04 Dec, 2028
(4 years from now)
Active
US12065432 Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid 04 Dec, 2028
(4 years from now)
Active
US8653103 Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid 04 Dec, 2028
(4 years from now)
Active
US9150552 Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid 04 Dec, 2028
(4 years from now)
Active
US8324242 Modulators of ATP-binding cassette transporters 05 Aug, 2027
(2 years from now)
Active
US7495103 Modulators of ATP-binding cassette transporters 20 May, 2027
(2 years from now)
Active
US8410274 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
(2 years from now)
Active
US8754224 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
(2 years from now)
Active
US9670163 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
(2 years from now)
Active
US9931334 Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
(2 years from now)
Active
US7973038 Modulators of ATP-binding cassette transporters 08 Nov, 2026
(2 years from now)
Active
US8741933 Modulators of ATP-binding cassette transporters 08 Nov, 2026
(2 years from now)
Active
US9216969 Modulators of ATP-binding cassette transporters 08 Nov, 2026
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orkambi's drug page


3. Symdeko (copackaged)

Symdeko (copackaged) is protected by 25 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10206877 Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases 14 Apr, 2035
(10 years from now)
Active
US11951212 Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases 14 Apr, 2035
(10 years from now)
Active
US10058546 Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof 15 Jul, 2033
(8 years from now)
Active
US9012496 Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof 15 Jul, 2033
(8 years from now)
Active
US10081621 Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide 25 Mar, 2031
(6 years from now)
Active
US11578062 Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide 25 Mar, 2031
(6 years from now)
Active
US10646481 Pharmaceutical composition and administrations thereof 13 Aug, 2029
(4 years from now)
Active
US11564916 Pharmaceutical composition and administrations thereof 13 Aug, 2029
(4 years from now)
Active
US8415387 Modulators of ATP-binding cassette transporters 12 Nov, 2027
(3 years from now)
Active
US8324242 Modulators of ATP-binding cassette transporters 05 Aug, 2027
(2 years from now)
Active
US7776905 Modulators of ATP-binding cassette transporters 03 Jun, 2027
(2 years from now)
Active
US7495103 Modulators of ATP-binding cassette transporters 20 May, 2027
(2 years from now)
Active
US7645789 Indole derivatives as CFTR modulators 01 May, 2027
(2 years from now)
Active
US8598181 Modulators of ATP-binding cassette transporters 01 May, 2027
(2 years from now)
Active
US8623905 Modulators of ATP-binding cassette transporters 01 May, 2027
(2 years from now)
Active
US10022352 Modulators of ATP-binding cassette transporters 09 Apr, 2027
(2 years from now)
Active
US10239867 Modulators of ATP-binding cassette transporters 09 Apr, 2027
(2 years from now)
Active
US11639347 Modulators of ATP-binding cassette transporters 09 Apr, 2027
(2 years from now)
Active
US9974781 Modulators of ATP-binding cassette transporters 09 Apr, 2027
(2 years from now)
Active
US8410274 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
(2 years from now)
Active
US8754224 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
(2 years from now)
Active
US9670163 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
(2 years from now)
Active
US9931334 Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
(2 years from now)
Active
US8354427 Modulators of ATP-binding cassette transporters 06 Jul, 2026
(1 year, 8 months from now)
Active
US8629162 Modulators of ATP-binding cassette transporters 24 Jun, 2025
(8 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symdeko (copackaged)'s drug page


4. Trikafta (copackaged)

Trikafta (copackaged) is protected by 32 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10793547 Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator 08 Dec, 2037
(13 years from now)
Active
US11179367 Pharmaceutical compositions for treating cystic fibrosis 08 Dec, 2037
(13 years from now)
Active
US11453655 Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator 08 Dec, 2037
(13 years from now)
Active
US11517564 Methods of treatment for cystic fibrosis 08 Dec, 2037
(13 years from now)
Active
US10758534 NA 06 Oct, 2035
(10 years from now)
Active
US11426407 Modulators of cystic fibrosis transmembrane conductance regulator 06 Oct, 2035
(10 years from now)
Active
US9012496 Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof 15 Jul, 2033
(8 years from now)
Active
US10272046 Pharmaceutical composition and administrations thereof 27 Feb, 2033
(8 years from now)
Active
US11147770 Pharmaceutical composition and administrations thereof 27 Feb, 2033
(8 years from now)
Active
US11752106 Pharmaceutical composition and administrations thereof 27 Feb, 2033
(8 years from now)
Active
US8883206 Pharmaceutical composition and administrations thereof 27 Feb, 2033
(8 years from now)
Active
US10081621 Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide 25 Mar, 2031
(6 years from now)
Active
US11578062 Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide 25 Mar, 2031
(6 years from now)
Active
US10646481 Pharmaceutical composition and administrations thereof 13 Aug, 2029
(4 years from now)
Active
US11564916 Pharmaceutical composition and administrations thereof 13 Aug, 2029
(4 years from now)
Active
US8415387 Modulators of ATP-binding cassette transporters 12 Nov, 2027
(3 years from now)
Active
US8324242 Modulators of ATP-binding cassette transporters 05 Aug, 2027
(2 years from now)
Active
US7776905 Modulators of ATP-binding cassette transporters 03 Jun, 2027
(2 years from now)
Active
US7495103 Modulators of ATP-binding cassette transporters 20 May, 2027
(2 years from now)
Active
US7645789 Indole derivatives as CFTR modulators 01 May, 2027
(2 years from now)
Active
US8598181 Modulators of ATP-binding cassette transporters 01 May, 2027
(2 years from now)
Active
US8623905 Modulators of ATP-binding cassette transporters 01 May, 2027
(2 years from now)
Active
US10022352 Modulators of ATP-binding cassette transporters 09 Apr, 2027
(2 years from now)
Active
US10239867 Modulators of ATP-binding cassette transporters 09 Apr, 2027
(2 years from now)
Active
US11639347 Modulators of ATP-binding cassette transporters 09 Apr, 2027
(2 years from now)
Active
US9974781 Modulators of ATP-binding cassette transporters 09 Apr, 2027
(2 years from now)
Active
US8410274 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
(2 years from now)
Active
US8754224 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
(2 years from now)
Active
US9670163 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
(2 years from now)
Active
US9931334 Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide 28 Dec, 2026
(2 years from now)
Active
US8354427 Modulators of ATP-binding cassette transporters 06 Jul, 2026
(1 year, 8 months from now)
Active
US8629162 Modulators of ATP-binding cassette transporters 24 Jun, 2025
(8 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trikafta (copackaged)'s drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Vertex Pharms Inc News

Suzetrigine, a potential blockbuster painkiller from Vertex, to undergo FDA review in the coming year

31 Jul, 2024

Investing in 5 Pharmaceutical Stocks with High-Potential Drugs in Development, U.S. News Reports

20 Mar, 2024

Cystic fibrosis patients urge DPIIT to permit domestic production of CFTR modulators for accessibility

03 Feb, 2024

Potential New Medication Holds Promise for Alleviating Intense Pain Without Risk of Dependence - MediaPost

02 Feb, 2024

See More